Format

Send to

Choose Destination
Pain. 2013 Sep;154(9):1668-79. doi: 10.1016/j.pain.2013.05.021. Epub 2013 May 18.

HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.

Author information

1
King's College London, Wolfson Centre for Age-Related Diseases, London SE1 1UL, United Kingdom. franziska.denk@kcl.ac.uk

Abstract

Histone deacetylase inhibitors (HDACIs) interfere with the epigenetic process of histone acetylation and are known to have analgesic properties in models of chronic inflammatory pain. The aim of this study was to determine whether these compounds could also affect neuropathic pain. Different class I HDACIs were delivered intrathecally into rat spinal cord in models of traumatic nerve injury and antiretroviral drug-induced peripheral neuropathy (stavudine, d4T). Mechanical and thermal hypersensitivity was attenuated by 40% to 50% as a result of HDACI treatment, but only if started before any insult. The drugs globally increased histone acetylation in the spinal cord, but appeared to have no measurable effects in relevant dorsal root ganglia in this treatment paradigm, suggesting that any potential mechanism should be sought in the central nervous system. Microarray analysis of dorsal cord RNA revealed the signature of the specific compound used (MS-275) and suggested that its main effect was mediated through HDAC1. Taken together, these data support a role for histone acetylation in the emergence of neuropathic pain.

KEYWORDS:

Histone deacetylase; Histone deacetylase inhibitors; Neuropathic pain

PMID:
23693161
PMCID:
PMC3763368
DOI:
10.1016/j.pain.2013.05.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center